The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Jan 2017 18:13

RNS Number : 3869V
Motif Bio PLC
27 January 2017
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Available on Request 3,444*

 

BNY Norwich Union Nominees Limited 299,767*

 

Chase (GA Group) Nominees Limited 5,354,315*

 

State Street Nominees Limited 1,038,396*

*denotes direct interest

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

23 January 2017

6. Date on which issuer notified:

24 January 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 

3% change at Direct Interest Level (Box 8A)

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary Shares

 

GB00BVVT4H71

8,924,647* **

8,924,647* **

6,695,922

6,695,922

Not Disclosable

3.42%

Not Disclosable

*Includes Right to Recall Loaned Shares (1,217,172)

** Includes indirect shares (2,028,725). The current indirect share holding is not disclosable on this TR-1.

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

 

200,000*

 

*Direct interest

0.10%

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,895,922

3.52%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited & Friends Provident International Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Figures are based on the revised total number of voting rights of 195,885,228 as per the Company's 'Issue of Equity and Total Voting Rights' announcement of 9 January 2017.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFLTLIIDFID
Date   Source Headline
7th Mar 201912:07 pmRNSSecond Price Monitoring Extn
7th Mar 201912:02 pmRNSPrice Monitoring Extension
19th Feb 20197:00 amRNSConference Call and Webcast
18th Feb 20197:00 amRNSAmendment Agreement with Hercules Capital
15th Feb 20194:28 pmRNSHolding(s) in Company
15th Feb 20194:26 pmRNSHolding(s) in Company
14th Feb 20197:00 amRNSComplete Response Letter from the FDA
5th Feb 20197:00 amRNSExercise of Warrants
23rd Jan 20194:31 pmRNSExercise of Warrants
1st Nov 20184:40 pmRNSSecond Price Monitoring Extn
1st Nov 20184:35 pmRNSPrice Monitoring Extension
31st Oct 20187:00 amRNSJefferies London Healthcare Conference
30th Oct 20184:35 pmRNSPrice Monitoring Extension
16th Oct 20184:40 pmRNSSecond Price Monitoring Extn
16th Oct 20184:35 pmRNSPrice Monitoring Extension
3rd Oct 20188:01 amRNSMotif Bio Presents New Iclaprim Data at IDWeek
28th Sep 20187:01 amRNSMotif Bio Notes Statement from Amphion Innovations
25th Sep 20187:00 amRNSHalf-year Report
20th Sep 20187:00 amRNSUpcoming Scientific Conferences
5th Sep 20187:00 amRNSIclaprim Data presented at ESCMID/ASM Conference
29th Aug 20184:35 pmRNSPrice Monitoring Extension
21st Aug 20187:15 amRNSMotif Bio notes statement from Amphion Innovations
17th Aug 20187:00 amRNSIclaprim Data at ESCMID/ASM Conference
14th Aug 20184:49 pmRNSHolding(s) in Company
14th Aug 20184:48 pmRNSHolding(s) in Company
14th Aug 20187:00 amRNSFDA Acceptance of New Drug Application
9th Aug 20187:00 amRNSInvestor Events in August and September
8th Aug 20187:00 amRNSNotice of Allowance for Two U.S. Iclaprim Patents
2nd Aug 20184:35 pmRNSPrice Monitoring Extension
3rd Jul 20184:48 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSDirectorate Change
26th Jun 201811:57 amRNSExercise of Stock Options
19th Jun 20181:58 pmRNSResult of AGM
14th Jun 20187:00 amRNSMotif Bio Submits NDA for Iclaprim
11th Jun 201811:41 amRNSHolding(s) in Company
11th Jun 20187:00 amRNSMotif Bio present New Iclaprim Data at ASM Microbe
8th Jun 20185:08 pmRNSHolding(s) in Company
31st May 20187:00 amRNSJefferies Global Healthcare Conference
25th May 20184:04 pmRNSHolding(s) in Company
24th May 20184:39 pmRNSHolding(s) in Company
23rd May 20185:42 pmRNSHolding(s) in Company
23rd May 20187:00 amRNSMotif Bio notes statement from Amphion Innovations
17th May 20182:24 pmRNSResult of Placing
17th May 20189:55 amRNSProposed Placing to raise approximately £10m
9th May 20187:00 amRNSAppointment of Vice President,Clinical Development
8th May 20187:00 amRNSMotif Bio to Present Iclaprim Data at ASM Microbe
1st May 20187:00 amRNSREVIVE-2 Study Results Published in Journal
19th Apr 20187:00 amRNSNew Iclaprim Data being Presented at ECCMID 2018
17th Apr 20184:40 pmRNSSecond Price Monitoring Extn
17th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.